Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Guinebretière J[au]:

SWI/SNF chromatin remodeling and human malignancies. Masliah-Planchon J et al. Annu Rev Pathol. (2015)

Tumoral heterogeneity of breast cancer. Roulot A et al. Ann Biol Clin (Paris). (2016)

50-year-old man with a falcine mass. Tauziede-Espariat A et al. Brain Pathol. (2017)

Search results

Items: 1 to 50 of 127

1.

[Clear cell sarcoma or gastrointestinal neuroectodermal tumor (GNET) of the tongue? Case report and review of the literature of an extremely rare tumor localization].

Breton S, Dubois M, Geay JF, Gillebert Q, Tordjman M, Guinebretière JM, Denoux Y.

Ann Pathol. 2019 Apr;39(2):167-171. doi: 10.1016/j.annpat.2018.10.004. Epub 2018 Dec 13. French.

PMID:
30554833
2.

[Benign and malignant giant-cell rich lesions of bone: Pathological diagnosis with special emphasis on recent immunohistochemistry and molecular techniques].

Macagno N, Caselles K, Aubert S, Audard V, Gomez-Brouchet A, Galant C, Guinebretière JM, Karanian M, Larousserie F, Marie B, de Pinieux G, Bouvier C.

Ann Pathol. 2018 Apr;38(2):92-102. doi: 10.1016/j.annpat.2018.01.008. Epub 2018 Mar 23. Review. French.

PMID:
29580573
3.

[Histological diagnosis of bone tumors: Guidelines of the French committee of bone pathologists reference network on bone tumors (RESOS)].

Galant C, Bouvier C, Larousserie F, Aubert S, Audard V, Brouchet A, Marie B, Guinebretière JM, de Pinieux du Bouexic G; Groupe de Pathologistes du réseau INCA d’expertise pour les sarcomes osseux de RESOS.

Bull Cancer. 2018 Apr;105(4):368-374. doi: 10.1016/j.bulcan.2017.11.018. Epub 2018 Mar 11. Review. French.

PMID:
29540287
4.

COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients.

DE Cremoux P, Hamy AS, Lehmann-Che J, Scott V, Sigal B, Mathieu MC, Bertheau P, Guinebretière JM, Pierga JY, Giacchetti S, Brain E, Marty M, Asselain B, Spyratos F, Bièche I.

Anticancer Res. 2018 Mar;38(3):1485-1490.

PMID:
29491076
5.

Transcriptomic definition of molecular subgroups of small round cell sarcomas.

Watson S, Perrin V, Guillemot D, Reynaud S, Coindre JM, Karanian M, Guinebretière JM, Freneaux P, Le Loarer F, Bouvet M, Galmiche-Rolland L, Larousserie F, Longchampt E, Ranchere-Vince D, Pierron G, Delattre O, Tirode F.

J Pathol. 2018 May;245(1):29-40. doi: 10.1002/path.5053. Epub 2018 Mar 30.

PMID:
29431183
6.

Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers.

Hequet D, Callens C, Gentien D, Albaud B, Mouret-Reynier MA, Dubot C, Cottu P, Huchon C, Zilberman S, Berseneff H, Foa C, Salmon R, Roulot A, Lerebours F, Salomon A, Ghali N, Morel P, Li Q, Cayre A, Guinebretière JM, Hornberger J, Penault-Llorca F, Rouzier R.

PLoS One. 2017 Oct 18;12(10):e0185753. doi: 10.1371/journal.pone.0185753. eCollection 2017.

7.

CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial.

Gomez-Brouchet A, Illac C, Gilhodes J, Bouvier C, Aubert S, Guinebretiere JM, Marie B, Larousserie F, Entz-Werlé N, de Pinieux G, Filleron T, Minard V, Minville V, Mascard E, Gouin F, Jimenez M, Ledeley MC, Piperno-Neumann S, Brugieres L, Rédini F.

Oncoimmunology. 2017 Aug 24;6(9):e1331193. doi: 10.1080/2162402X.2017.1331193. eCollection 2017.

8.

[Genomic tests in early breast cancer management: Real-life experience].

Yazigi A, Callens C, Jaillot A, Lerebours F, Guinebretière JM, Rouzier R, Héquet D.

Bull Cancer. 2017 Oct;104(10):904-906. doi: 10.1016/j.bulcan.2017.07.002. Epub 2017 Aug 10. French. No abstract available.

PMID:
28803642
9.

50-year-old man with a falcine mass.

Tauziede-Espariat A, Adle-Biassette H, Simonneau A, Guinebretiere JM, Polivka M.

Brain Pathol. 2017 May;27(3):403-404. doi: 10.1111/bpa.12510. No abstract available.

PMID:
28414886
10.

Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.

Giacchetti S, Hamy AS, Delaloge S, Brain E, Berger F, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Saghatchian M, Lerebours F, Mazouni C, Tembo O, Espié M, Reyal F, Marty M, Asselain B, Pierga JY.

Eur J Cancer. 2017 Apr;75:323-332. doi: 10.1016/j.ejca.2017.01.008. Epub 2017 Mar 7.

PMID:
28279941
11.

Denaturing fixatives are compatible with the NanoString nCounter® platform and the Prosigna® assay.

Rouzier R, Roulot A, Jeiranian AH, Ram N, Guinebretiere JM, Salomon AV, Gentien D.

N Biotechnol. 2017 May 25;36:37-41. doi: 10.1016/j.nbt.2017.01.001. Epub 2017 Jan 6.

PMID:
28069519
12.

Tumoral heterogeneity of breast cancer.

Roulot A, Héquet D, Guinebretière JM, Vincent-Salomon A, Lerebours F, Dubot C, Rouzier R.

Ann Biol Clin (Paris). 2016 Dec 1;74(6):653-660. Review.

PMID:
27848916
13.

BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.

Hamy AS, Bieche I, Lehmann-Che J, Scott V, Bertheau P, Guinebretière JM, Matthieu MC, Sigal-Zafrani B, Tembo O, Marty M, Asselain B, Spyratos F, de Cremoux P.

Breast Cancer Res Treat. 2016 Oct;159(3):499-511. doi: 10.1007/s10549-016-3961-2. Epub 2016 Sep 3.

PMID:
27592112
14.

Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas Subtypes.

Meseure D, Vacher S, Drak Alsibai K, Trassard M, Nicolas A, Leclere R, Lerebours F, Guinebretiere JM, Marangoni E, Lidereau R, Bieche I.

Cancer Microenviron. 2016 Dec;9(2-3):107-118. doi: 10.1007/s12307-016-0186-1. Epub 2016 Jul 9.

15.

An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer.

Wesseling J, Tinterri C, Sapino A, Zanconati F, Lutke-Holzik M, Nguyen B, Deck KB, Querzoli P, Perin T, Giardina C, Seitz G, Guinebretière JM, Barone J, Dekker L, de Snoo F, Stork-Sloots L, Roepman P, Watanabe T, Cusumano P.

Virchows Arch. 2016 Sep;469(3):297-304. doi: 10.1007/s00428-016-1979-9. Epub 2016 Jul 4.

PMID:
27377889
16.

Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.

Piperno-Neumann S, Le Deley MC, Rédini F, Pacquement H, Marec-Bérard P, Petit P, Brisse H, Lervat C, Gentet JC, Entz-Werlé N, Italiano A, Corradini N, Bompas E, Penel N, Tabone MD, Gomez-Brouchet A, Guinebretière JM, Mascard E, Gouin F, Chevance A, Bonnet N, Blay JY, Brugières L; Sarcoma Group of UNICANCER; French Society of Pediatric Oncology (SFCE); French Sarcoma Group (GSF-GETO).

Lancet Oncol. 2016 Aug;17(8):1070-1080. doi: 10.1016/S1470-2045(16)30096-1. Epub 2016 Jun 17.

PMID:
27324280
17.

Mechanical Signals Inhibit Growth of a Grafted Tumor In Vivo: Proof of Concept.

Brossel R, Yahi A, David S, Moreno Velasquez L, Guinebretière JM.

PLoS One. 2016 Apr 21;11(4):e0152885. doi: 10.1371/journal.pone.0152885. eCollection 2016.

18.

[Shall all lobular intraepithelial neoplasia diagnosed on image-guided biopsy require a surgical management?].

Fischer-Hunsinger M, Guinebretière JM, Lasry S, Langer A, Berment H, Nekka I, Nodiot P, Cherel P.

Bull Cancer. 2016 May;103(5):421-33. doi: 10.1016/j.bulcan.2016.02.012. Epub 2016 Apr 12. French.

PMID:
27084199
19.

Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma.

Rossi L, Laas E, Mallon P, Vincent-Salomon A, Guinebretiere JM, Lerebours F, Rouzier R, Pierga JY, Reyal F.

Br J Cancer. 2015 Sep 29;113(7):996-1002. doi: 10.1038/bjc.2015.239. Epub 2015 Sep 17.

20.

Pathological Characteristics of Both Tumors in Bifocal and Bicentric Breast Cancer.

Mosbah R, Rouzier R, Guinebretière JM, Falcou MC, Stevens D, Héquet D.

Anticancer Res. 2015 Sep;35(9):5111-6.

PMID:
26254415
21.

Comments on Carter et al's "activating GNAS mutations in parosteal osteosarcoma".

Tabareau-Delalande F, Collin C, Larousserie F, Bouvier C, Gomez-Brouchet A, Aubert S, Guinebretière JM, Decouvelaere AV, de Muret A, Pagès JC, de Pinieux G.

Am J Surg Pathol. 2015 Jul;39(7):1010-3. doi: 10.1097/PAS.0000000000000461. No abstract available.

PMID:
25970689
22.

SWI/SNF chromatin remodeling and human malignancies.

Masliah-Planchon J, Bièche I, Guinebretière JM, Bourdeaut F, Delattre O.

Annu Rev Pathol. 2015;10:145-71. doi: 10.1146/annurev-pathol-012414-040445. Epub 2014 Oct 27. Review.

PMID:
25387058
23.

[Use of guidelines and heterogeneity of decision making for adjuvant chemotherapy in hormone-receptor positive, HER2-negative, early breast cancer: results of a French national survey].

Fekih M, Petit T, Zarca D, Guinebretière JM, André F, Pierga JY, Namer M, Gligorov J, Delaloge S.

Bull Cancer. 2014 Oct;101(10):918-24. doi: 10.1684/bdc.2014.2030. French.

PMID:
25373691
24.

Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: experience of the REMAGUS 02 phase II trial.

Valet F, de Cremoux P, Spyratos F, Servant N, Dujaric ME, Gentien D, Lehmann-Che J, Scott V, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Pierga JY, Delaloge S, Giacchetti S, Brain E, Tembo O, Marty M, Asselain B.

Breast. 2013 Dec;22(6):1052-9. doi: 10.1016/j.breast.2013.08.015. Epub 2013 Oct 2.

PMID:
24095610
25.

SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.

Jacquemier J, Spyratos F, Esterni B, Mozziconacci MJ, Antoine M, Arnould L, Lizard S, Bertheau P, Lehmann-Che J, Fournier CB, Krieger S, Bibeau F, Lamy PJ, Chenard MP, Legrain M, Guinebretière JM, Loussouarn D, Macgrogan G, Hostein I, Mathieu MC, Lacroix L, Valent A, Robin YM, Revillion F, Triki ML, Seaume A, Salomon AV, de Cremoux P, Portefaix G, Xerri L, Vacher S, Bièche I, Penault-Llorca F.

BMC Cancer. 2013 Jul 22;13:351. doi: 10.1186/1471-2407-13-351.

26.

Rare overexpression of anaplastic lymphoma kinase gene in inflammatory and non-inflammatory breast cancer.

Lerebours F, Callens C, Vacher S, Hatem R, Guinebretière JM, Bièche I.

Eur J Cancer. 2013 Aug;49(12):2774-6. doi: 10.1016/j.ejca.2013.04.010. Epub 2013 May 8. No abstract available.

PMID:
23664096
27.

A short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation.

Weiswald LB, Richon S, Massonnet G, Guinebretière JM, Vacher S, Laurendeau I, Cottu P, Marangoni E, Nemati F, Validire P, Bellet D, Bièche I, Dangles-Marie V.

Br J Cancer. 2013 Apr 30;108(8):1720-31. doi: 10.1038/bjc.2013.132. Epub 2013 Mar 28.

28.

KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance.

Dijkstra JR, Heideman DA, Meijer GA, Boers JE, 't Hart NA, Diebold J, Hirschmann A, Hoefler G, Winter G, Miltenberger-Miltenyi G, Pereira SV, Richman SD, Quirke P, Rouleau EL, Guinebretiere JM, Tejpar S, Biesmans B, van Krieken JH.

Virchows Arch. 2013 Jan;462(1):39-46. doi: 10.1007/s00428-012-1356-2. Epub 2012 Dec 15.

PMID:
23242173
29.

Non-sentinel lymph node metastasis prediction in breast cancer with metastatic sentinel lymph node: impact of molecular subtypes classification.

Reyal F, Belichard C, Rouzier R, de Gournay E, Senechal C, Bidard FC, Pierga JY, Cottu P, Lerebours F, Kirova Y, Feron JG, Fourchotte V, Vincent-Salomon A, Guinebretiere JM, Sigal-Zafrani B, Sastre-Garau X, De Rycke Y, Coutant C.

PLoS One. 2012;7(10):e47390. doi: 10.1371/journal.pone.0047390. Epub 2012 Oct 9.

30.

A case of osteosarcoma in a patient with pycnodysostosis.

Cortisse N, Forget P, Dresse MF, Florkin B, Mascard E, Guinebretière JM, Brugières L, Hoyoux C.

J Pediatr Hematol Oncol. 2012 Oct;34(7):545-7.

31.

How to read a pathology report of a bone tumor.

Guinebretière JM, Kreshak J, Suciu V, Maulmont CD, Mascard E, Missenard G, Larousserie F, Vanel D.

Eur J Radiol. 2013 Dec;82(12):2092-9. doi: 10.1016/j.ejrad.2011.11.036. Epub 2012 Jan 4.

PMID:
22225961
32.

[Place of the pathologist in the management of primary bone tumors (osteosarcoma and Ewing's family tumors after neoadjuvant treatment)].

Gomez-Brouchet A, Bouvier C, Decouvelaere AV, Larousserie F, Aubert S, Leroy X, Guinebretière JM, Coulomb A, Cassagnau E, de Muret A, Audard V, Marie B, de Pinieux G.

Ann Pathol. 2011 Dec;31(6):455-65. doi: 10.1016/j.annpat.2011.10.009. Epub 2011 Nov 29. Review. French.

PMID:
22172118
33.

Is there a link between osteofibrous dysplasia and adamantinoma?

Ramanoudjame M, Guinebretière JM, Mascard E, Seringe R, Dimeglio A, Wicart P.

Orthop Traumatol Surg Res. 2011 Dec;97(8):877-80. doi: 10.1016/j.otsr.2011.09.008. Epub 2011 Nov 11.

34.

Rates of upgrade to malignancy for 271 cases of flat epithelial atypia (FEA) diagnosed by breast core biopsy.

Peres A, Barranger E, Becette V, Boudinet A, Guinebretiere JM, Cherel P.

Breast Cancer Res Treat. 2012 Jun;133(2):659-66. doi: 10.1007/s10549-011-1839-x. Epub 2011 Nov 1.

PMID:
22042365
35.

Clinical characteristics and prognosis of osteosarcoma in young children: a retrospective series of 15 cases.

Guillon MA, Mary PM, Brugière L, Marec-Bérard P, Pacquement HD, Schmitt C, Guinebretière JM, Tabone MD.

BMC Cancer. 2011 Sep 24;11:407. doi: 10.1186/1471-2407-11-407.

36.

[The lesions of flat epithelial atypia diagnosed on breast biopsy].

Peres A, Becette V, Guinebretiere JM, Cherel P, Barranger E.

Gynecol Obstet Fertil. 2011 Oct;39(10):579-85. doi: 10.1016/j.gyobfe.2011.04.002. Epub 2011 Sep 15. French.

PMID:
21924938
37.

[Vascular tumors and pseudo-tumors. Well-differentiated angiosarcoma].

Guinebretière JM.

Ann Pathol. 2011 Aug;31(4):276-80. doi: 10.1016/j.annpat.2011.04.013. Epub 2011 Jul 7. French. No abstract available.

PMID:
21839352
38.

Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients.

de Cremoux P, Valet F, Gentien D, Lehmann-Che J, Scott V, Tran-Perennou C, Barbaroux C, Servant N, Vacher S, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Asselain B, Marty M, Spyratos F.

BMC Cancer. 2011 Jun 1;11:215. doi: 10.1186/1471-2407-11-215.

39.

Breast mass with intense 99mTc-diphosphonate uptake revealing primary breast osteosarcoma.

Coussy F, Le Scodan R, Guinebretiere JM, Langer A, Lerebours F.

J Clin Oncol. 2011 May 20;29(15):e428-30. doi: 10.1200/JCO.2010.33.6719. Epub 2011 Mar 7. No abstract available.

PMID:
21383295
40.

Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas.

Rodrigues MJ, Wassermann J, Albiges L, Brain E, Delaloge S, Stevens D, Guinebretière JM, Mathieu MC, Kirova Y, Guillot E, Vincent-Salomon A, Cottu PH.

J Clin Oncol. 2010 Oct 1;28(28):e541-2. doi: 10.1200/JCO.2010.29.7952. Epub 2010 Jul 26. No abstract available.

PMID:
20660834
41.

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.

Pierga JY, Delaloge S, Espié M, Brain E, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Spielmann M, Savignoni A, Marty M.

Breast Cancer Res Treat. 2010 Jul;122(2):429-37. doi: 10.1007/s10549-010-0939-3. Epub 2010 May 18.

PMID:
20480225
42.

In situ protein expression in tumour spheres: development of an immunostaining protocol for confocal microscopy.

Weiswald LB, Guinebretière JM, Richon S, Bellet D, Saubaméa B, Dangles-Marie V.

BMC Cancer. 2010 Mar 22;10:106. doi: 10.1186/1471-2407-10-106.

43.

[Apocrine lesions in breast pathology].

Suciu V, Menet E, Guinebretière JM, Trassard M, Vielh P.

Ann Pathol. 2009 Nov;29 Spec No 1:S112-3. doi: 10.1016/j.annpat.2009.07.019. Epub 2009 Oct 14. Review. French. No abstract available.

PMID:
19887237
44.

Cancer is heterogeneous.

Guinebretiere JM.

J Clin Oncol. 2009 Jun 1;27(16):2732; author reply 2734-5. doi: 10.1200/JCO.2008.21.7646. Epub 2009 Apr 20. No abstract available.

PMID:
19380436
45.

KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition.

Rouleau E, Spyratos F, Dieumegard B, Guinebretière JM, Lidereau R, Bièche I.

Br J Cancer. 2008 Dec 16;99(12):2100. doi: 10.1038/sj.bjc.6604815. No abstract available.

46.

A six-gene signature predicting breast cancer lung metastasis.

Landemaine T, Jackson A, Bellahcène A, Rucci N, Sin S, Abad BM, Sierra A, Boudinet A, Guinebretière JM, Ricevuto E, Noguès C, Briffod M, Bièche I, Cherel P, Garcia T, Castronovo V, Teti A, Lidereau R, Driouch K.

Cancer Res. 2008 Aug 1;68(15):6092-9. doi: 10.1158/0008-5472.CAN-08-0436.

47.

CXC chemokines located in the 4q21 region are up-regulated in breast cancer.

Bièche I, Chavey C, Andrieu C, Busson M, Vacher S, Le Corre L, Guinebretière JM, Burlinchon S, Lidereau R, Lazennec G.

Endocr Relat Cancer. 2007 Dec;14(4):1039-52.

48.

BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.

Monnerat C, Chompret A, Kannengiesser C, Avril MF, Janin N, Spatz A, Guinebretière JM, Marian C, Barrois M, Boitier F, Lenoir GM, Bressac-de Paillerets B.

Fam Cancer. 2007;6(4):453-61. Epub 2007 Jul 12.

PMID:
17624602
49.

[1879, Ernest Besnier inventor of the word "biopsy"].

Nezelof C, Guinebretière JM.

Rev Prat. 2006 Nov 30;56(18):2081-5. French. No abstract available.

PMID:
17274517
50.

SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.

Le Deley MC, Guinebretière JM, Gentet JC, Pacquement H, Pichon F, Marec-Bérard P, Entz-Werlé N, Schmitt C, Brugières L, Vanel D, Dupoüy N, Tabone MD, Kalifa C; Société Française d'Oncologie Pédiatrique (SFOP).

Eur J Cancer. 2007 Mar;43(4):752-61. Epub 2007 Jan 30.

PMID:
17267204

Supplemental Content

Loading ...
Support Center